Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome

Abstract

This study suggests that R115777 has modest activity in MDS patients, but that, in this patient population, 4 weeks of daily doses of 600 mg PO bid is not tolerated. Further exploration of the optimal dose/schedule and correlation with biologic end points are warranted.